Results 61 to 70 of about 3,283 (198)

Integrated Population Pharmacokinetic Analysis of Intravitreal Aflibercept Drug Products

CPT: Pharmacometrics &Systems Pharmacology, Volume 15, Issue 7, July 2026.
ABSTRACT Neovascular age‐related macular degeneration (nAMD) and diabetic macular edema (DME) can cause substantial vision loss. The 2‐mg drug product of aflibercept (AFL‐2)—an anti‐vascular endothelial growth factor agent—has established efficacy and safety in both diseases.
Sébastien Bihorel, Joannellyn Chiu, Jason Chittenden, Thomas Eissing, Kenneth C. Turner, Joachim Höchel, Torsten Zimmermann, Zhongqing Will He, John D. Davis, A. Thomas DiCioccio, Lutz O. Harnisch   +10 more
wiley   +1 more source

Real-world outcomes of a loading phase with intravitreal faricimab in refractory Neovascular Age-Related Macular Degeneration (nAMD) patients

BMC Ophthalmology
Intravitreal injection (IVI) of anti-vascular endothelial growth factor (anti-VEGF) agents is the standard of care for neovascular age-related macular degeneration (nAMD), but treatment resistance and incomplete fluid resolution remain challenges in ...
Yufeng Xu, Ning-Xi Hong, Ming-Zhi Su, Wei-Xin Zheng, Panpan Ye   +4 more
semanticscholar   +1 more source

Real world outcomes of faricimab in treatment resistant neovascular age-related macular degeneration among Asian patients

Scientific Reports
To describe the real-world efficacy and safety outcome measurements of faricimab use in treatment-resistant neovascular age-related macular degeneration (nAMD) in a cohort of Asian patients.
Elvine Zhong Oen Neo, Kevin Wei Onn Liang, Zhi Hong Toh, Andrew Bee Yong Tan, Darren Mun Yoong Choy, Wenting Zhou, Helen Fang Mi, Louis Wei Yi Lim, Yu Qiang Soh, Jacob Yu Hang Chin, Zheng Xian Thng, Karen Jhi Wen Chia, Augustinus Laude, Colin Siang Hui Tan, Tock Han Lim, Nicola Yi’an Gan, Rajesh Rajagopalan, Wei Kiong Ngo   +17 more
doaj   +1 more source

Proteolytic remodelling of the extracellular matrix by pericytes

The FEBS Journal, Volume 293, Issue 13, Page 3899-3953, July 2026.
Pericytes are specialised perivascular cells intimately connected with endothelial cells and essential for the maintenance of vascular beds. They contribute to the formation and remodelling of the extracellular matrix by actively secreting proteases and protease inhibitors.
Tina Burkhard, Ella Milne, Kate Qian, Paola Campagnolo, Salvatore Santamaria   +4 more
wiley   +1 more source

Economic Benefit of Aflibercept 8 mg Versus Faricimab for Neovascular Age-Related Macular Degeneration or Diabetic Macular Edema in the US

Ophthalmology and Therapy
Introduction The aim of this study was to compare the estimated direct and indirect costs with aflibercept 8 mg and faricimab in patients with neovascular age-related macular degeneration (nAMD) or diabetic macular edema (DME) over 5 years.
Andreas Kuznik, Anna Coughlan, Amy Pinsent, Hector Toro-Diaz, Steven Sherman, Nimesh Patel   +5 more
doaj   +1 more source

Adverse event reporting of faricimab: a disproportionality analysis of FDA adverse event reporting system (FAERS) database

Frontiers in Pharmacology
Background Faricimab is the first and only bispecific antibody approved by the U.S. Food and Drug Administration (FDA) for intravitreal injection. Given its increasingly widespread use in retinal vascular diseases, understanding its adverse events (AEs ...
Chang-Zhu He, Q. Qiu, Song-Jie Lu, Fu-Li Xue, Jun-Qiao Liu, Yu He   +5 more
semanticscholar   +1 more source

Early high‐dose aflibercept 8 mg clinical outcomes in wet age‐related macular degeneration patients resistant to aflibercept 2 mg or faricimab

Acta Ophthalmologica, Volume 104, Issue 7, Page e885-e887, November 2026.
Pinja Sutinen, Idan Hecht, Raimo Tuuminen   +2 more
wiley   +1 more source

Real‐world outcomes of aflibercept 8 mg in patients previously treated for neovascular age‐related macular degeneration

Acta Ophthalmologica, Volume 104, Issue 3, Page 296-304, May 2026.
Abstract Purpose To evaluate visual, anatomical and safety outcomes of aflibercept 8 mg in previously treated patients with neovascular age‐related macular degeneration (nAMD). Methods This retrospective study included nAMD patients switched to aflibercept 8 mg from prior anti‐VEGF therapies at Sahlgrenska University Hospital between February 2024 and ...
Imadeddin Abu Ishkheidem, Esra Inci, Martin Breimer, Sofia Töyrä Silfverswärd, Madeleine Zetterberg, Marita Andersson Grönlund   +5 more
wiley   +1 more source

Summary of Research: Cost‑Effectiveness of Faricimab in the Treatment of Diabetic Macular Oedema (DMO): A UK Analysis

Ophthalmology and Therapy
This is a summary of the original article ‟Cost‑Effectiveness of Faricimab in the Treatment of Diabetic Macular Oedema (DMO): A UK Analysis”. DMO, a serious eye condition that can lead to vision loss in people with diabetes, is a significant health ...
Christian Bührer, Thomas Paling, Richard Gale, Tatiana Paulo, Marloes Bagijn   +4 more
doaj   +1 more source

Twelve‐Month Real‐World Outcomes of Faricimab for Treatment‐Naive Neovascular AMD in Australia

Clinical &Experimental Ophthalmology, Volume 54, Issue 4, Page 500-506, May/June 2026.
ABSTRACT Background To provide insights into the effectiveness and safety of faricimab for treatment‐naïve eyes with neovascular age‐related macular degeneration (nAMD). Methods A retrospective cohort study using a prospectively‐designed registry. Treatment‐naïve eyes with nAMD in Australia starting treatment with faricimab between Jan 2023–Sep 2024 ...
Mark Gillies, Yohei Hashimoto, Rahman Nazari, Jennifer Arnold, Beibei Wang, Richard Barry, Ross Ferrier, Justin Game, Daniel Barthelmes   +8 more
wiley   +1 more source